Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Characteristics of dermal fibroblasts and their biotherapeutic value in musculoskeletal system diseases

Zhou L., Zhang Q., Yang H., Zhang G., Fan M., Jin R.

Clinical Trial on Cartilage Damage, Tendon Injury, Disc Degeneration, Chronic Inflammation, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Front Bioeng Biotechnol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42339466
PMCID
PMC13284054
DOI
10.3389/fbioe.2026.1821137

Abstract (original English)

As the principal functional cells in the dermal layer of the skin, dermal fibroblasts can not only synthesize and remodel extracellular matrix components such as collagen and elastin, but also secrete a variety of growth factors and exert immunomodulatory functions. They play a pivotal role in maintaining skin structural homeostasis and wound repair, and their unique biological properties also make them a key subject of research in regenerative medicine. Musculoskeletal diseases (such as tendinopathy, fracture and intervertebral disc degeneration) are often accompanied by insufficient local tissue repair capacity, chronic inflammation and extracellular matrix degradation. In recent years, autologous or allogeneic fibroblast transplantation therapy has attracted increasing attention in orthopedic regenerative medicine. A number of clinical trials and basic studies have confirmed the beneficial effects of fibroblasts in promoting cartilage repair, alleviating inflammatory responses, improving tendon healing, and delaying intervertebral disc degeneration. This review systematically examines the sources, phenotypes, and functional characteristics of dermal fibroblasts. It focuses on their therapeutic potential in musculoskeletal system diseases (MSDs), including tendon injury, disc degeneration, and fracture healing. At the same time, it analyzes the challenges faced by current app

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research